Currently Viewing:
Currently Reading
Unmet Care Targets Suggest Need for Improved Diabetes Care Accessibility
August 18, 2019 – Alison Rodriguez
Blood Clots in MPN Related to Higher Cost, Length of Stay for Patients With MPN
August 17, 2019 – AJMC Staff
Researchers Seek to Determine Genetic Variability in Parkinson Progression
August 17, 2019 – AJMC Staff
FDA Panel Backs Use of Descovy for HIV Prevention in Men, Transgender Women
August 16, 2019 – Jaime Rosenberg
Researcher Excited About Future of Psoriasis Treatment
August 16, 2019 – Allison Inserro
This Week in Managed Care: August 16, 2019
August 16, 2019
AJMC® in the Press, August 16, 2019
August 16, 2019 – AJMC Staff
Pediatric Leukemia Treatment Linked to Increased Risk of Infections, Study Finds
August 16, 2019 – Alison Rodriguez
5 Findings From the August 2019 Issue of AJMC®
August 16, 2019 – Christina Mattina

What We're Reading: Opioid Prescription Disparities; Trump Backs Drug Import Plan; High Cost of Drugs Approved in 2018

AJMC Staff
White patients are significantly more likely to be prescribed buprenorphine compared with patients of other races/ethnicities; Trump has backed a Florida proposal to import drugs from Canada; nearly 25% of medications approved in 2018 cost more than $30,000 per year.

White Patients More Likely to Be Prescribed Opioids

Between 2012 and 2015, white populations were almost 35 times more likely to be prescribed buprenorphine than patients of other races/ethnicities (12.7 million vs 363,000), according to a study published in JAMA Psychiatry. The study also found that buprenorphine treatment was concentrated among those with private insurance and those who self-pay. The study combined data from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey outpatient department component.

Trump Backs Plan to Import Drugs From Canada

President Donald Trump has approved Florida’s proposal to import prescription drugs from Canada, breaking from some Republicans, including Senator Lamar Alexander, R-Tennessee, who chairs the Senate Committee on Health, Education, Labor, and Pensions. In order for the proposal to be implemented, HHS Secretary Alex Azar would have to certify that the imported drugs would be safe, reported The Hill. Azar has previously voiced concerns with the idea, but in a press call earlier this week, he said the administration supports importation if it can be done safely.


1 in 4 Prescriptions Approved in 2018 Cost Over $30,000

Out of approximately 100 medications approved in 2018, 23 of them came with a list price of more than $30,000 per year for a course of treatment, according to an analysis from GoodRx. Many of the approved drugs, which have prices ranging from $35,839 to $573,820, are to treat specific cancers, such as ivosidenib (Tibsovo) for acute myeloid leukemia, which costs $317,733. Others were approved for rare conditions, including migalastat (Galafold), which costs $315,250. Other drugs that topped the list include lanadelumab-flyo (Takhzyro) for hereditary angioedema and larotrectinib (Vitrakvi) for solid tumors expressing neurotrophic receptor tyrosine kinase.

Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up